NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

黑色素瘤:競爭情形 (∼2026年)

Melanoma - Competitive Landscape to 2026

出版商 GlobalData 商品編碼 995609
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
黑色素瘤:競爭情形 (∼2026年) Melanoma - Competitive Landscape to 2026
出版日期: 2020年10月30日內容資訊: 英文 60 Pages
簡介

以PD-1作為標的免疫療法,是對藥物開發企業來說的關心領域。在開發平台有689種藥物,其中47種以PD-1作為標的。大型製藥企業在黑色素瘤研究開發中具支配性,BMS, Roche, Novartis, GSK, Merck & Co. 和 Pfizer領導,預計促進黑色素瘤市場成長。

本報告提供黑色素瘤 治療關於現在及未來的競爭情形資料,疾病概要,成藥,開發平台,臨床試驗,及評估等資訊彙整。

目錄

第1章 目錄

  • 序文
  • 簡稱
  • 相關報告
  • 今後的相關報告

第2章 摘要整理

  • 主要調查結果
  • 重要的活動

第3章 簡介

  • 調查範圍
  • 疾病概要、流行病學概要
  • 流行病學

第4章 成藥的評估

  • 成藥概要
  • 成藥的簡介

第5章 開發平台評估

  • 開發平台概要
  • 開發平台的明細:各地區
  • 開發平台的明細:各分子類型及標的
  • 藥物的優先審查指定
  • 相變的成功率
  • 核準的可能性

第6章 臨床試驗的評估

  • 臨床試驗概要:各階段
  • 各地區的概要
  • 治療領域的展望
  • 主要贊助商
  • 登記分析
  • 實行可能性分析

第7章 商業性評估

  • 今後的市場促進因素

第8章 社群媒體與數位行銷

  • 主要的Twitter Chatter
  • 頂級品牌的網站
  • >信任來源和引用來源

第9章 附錄

  • 調查手法
  • 關於作者
  • 關於GlobalData
  • 諮詢方式
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC029CL

GlobalData's "Melanoma - Competitive Landscape to 2026" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

PD-1 targeting immunotherapies are the major focus of drug developers. There are 689 drugs in the pipeline, 47 of which targets PD-1. Big pharma dominates R&D in this indication, with BMS, Roche, Novartis, GSK, Merck & Co. and Pfizer leading the way. Increasing incidence expected to drive the growth in Melanoma market.

This reports provides a data-driven overview of the current and future competitive landscape in melanoma therapeutics.

Scope

Components of the report include -

  • Disease epidemiology
  • Marketed drugs assessment
  • Pipeline drugs assessment
  • Clinical trials assessment
  • Commercial assessment
  • Social media overview
  • Digital marketing overview

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global melanoma market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1.Table of Contents

  • 1.1 Preface
  • 1.2 Abbreviations
  • 1.3 Related Reports
  • 1.4 Upcoming Related Reports

2 Executive Summary

  • 2.1 Key Findings
  • 2.2 Key Events

3 Introduction

  • 3.1 Report Scope
  • 3.2 Disease Overview Epidemiology Overview
  • 3.3 Epidemiology

4 Marketed Drugs Assessment

  • 4.1 Marketed Drugs Overview
  • 4.2 Marketed Drug Profiles

5 Pipeline Assessment

  • 5.1 Pipeline Overview
  • 5.2 Pipeline Breakdown by Region
  • 5.3 Pipeline Breakdown by Molecule Type and Target
  • 5.4 Drug Review Designations
  • 5.5 Phase Transition Success Rates
  • 5.6 Likelihood of Approval

6 Clinical Trial Assessment

  • 6.1 Clinical Trials Overview by Phase
  • 6.2 Overview by Region
  • 6.4 Therapy Area Perspective
  • 6.4 Leading Sponsors
  • 6.5 Enrollment Analytics
  • 6.6 Feasibility Analysis

7 Commercial Assessment

  • 7.1 Upcoming Market Catalysts

8 Social Media and Digital Marketing

  • 8.1 Key Twitter Chatter
  • 8.2 Top Branded Websites
  • 8.3 Trust Flow and Citation Flow

9 Appendix

  • 9.1 Methodology
  • 9.2 About the Authors
  • 9.3 About GlobalData
  • 9.4 Contact Us
  • 9.5 Disclaimer